Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Sees Large Increase in Short Interest

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the target of a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 1,098 shares, an increase of 237.8% from the July 30th total of 325 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 3,918 shares, the short-interest ratio is presently 0.3 days.

Fidelity Disruptive Medicine ETF Price Performance

FMED stock opened at $32.49 on Thursday. The company has a fifty day moving average price of $29.23 and a 200 day moving average price of $26.55. Fidelity Disruptive Medicine ETF has a 12 month low of $23.48 and a 12 month high of $32.89. The company has a market cap of $51.98 million, a price-to-earnings ratio of 41.33 and a beta of 0.75.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC grew its holdings in shares of Fidelity Disruptive Medicine ETF by 0.8% during the first quarter. Jane Street Group LLC now owns 66,382 shares of the company’s stock worth $1,567,000 after buying an additional 499 shares during the last quarter. Vise Technologies Inc. acquired a new position in Fidelity Disruptive Medicine ETF in the 4th quarter valued at about $234,000. Finally, Virtu Financial LLC purchased a new stake in Fidelity Disruptive Medicine ETF during the 4th quarter valued at approximately $228,000.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.